AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20886400 — intervention group
Group type: COMPARATOR
Intervention: Nonfluoroscopy during oral double-balloon enteroscopy (DBE)
Number of subjects: 156
Study 17976788 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based data entry model for documenting ED overcrowding
Number of subjects: 18
Study 16393237 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber intake (quartile 4 vs quartile 1)
Number of subjects: 1520
Study 16393237 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber intake (specifically for proximal colon)
Number of subjects: 1520
Study 16393237 — intervention group
Group type: EXPERIMENTAL
Intervention: Processed meat intake (quartile 4 vs quartile 1)
Number of subjects: 1520
Study 16393237 — intervention group
Group type: EXPERIMENTAL
Intervention: Chicken intake (quartile 4 vs quartile 1)
Number of subjects: 1520
Study 16393237 — intervention group
Group type: COMPARATOR
Intervention: Fat intake
Number of subjects: 1520
Study 16393237 — intervention group
Group type: COMPARATOR
Intervention: Total red meat intake
Number of subjects: 1520
Study 12915873 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel community-based service
Number of subjects: 373
Study 12915873 — intervention group
Group type: COMPARATOR
Intervention: Standard regional service
Number of subjects: 373
Study 10596521 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief motivational interview (MI)
Number of subjects: 94
Study 10596521 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 94
Study 8709665 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote-simultaneous interpretation
Number of subjects: 49
Study 8709665 — intervention group
Group type: COMPARATOR
Intervention: Proximate-consecutive interpretation
Number of subjects: 49
Study 1833900 — intervention group
Group type: EXPERIMENTAL
Intervention: Amrinone
Number of subjects: 42
Study 1833900 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone (1 mg/kg bw)
Number of subjects: 42
Study 1833900 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone (1.5 mg/kg bw)
Number of subjects: 42
Study 1833900 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphodiesterase inhibitors (general)
Number of subjects: 42
Study 6213379 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical erythromycin 1.5 percent solution
Number of subjects: 66
Study 6213379 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical clindamycin phosphate 1.0 percent solution
Number of subjects: 66
Study 30954433 — intervention group
Group type: EXPERIMENTAL
Intervention: Human Growth Hormone (HGH)
Number of subjects: 113
Study 30954433 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113
Study 27680881 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine
Number of subjects: 8192
Study 27680881 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8192
Study 26371397 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin-D sufficiency (VDS)
Number of subjects: 398
Study 26371397 — intervention group
Group type: COMPARATOR
Intervention: Vitamin-D deficiency (VDD)
Number of subjects: 398
Study 26371397 — intervention group
Group type: COMPARATOR
Intervention: Vitamin-D insufficiency (VDI)
Number of subjects: 398
Study 24841352 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound (US)‐guided access to the subclavian vein
Number of subjects: 403
Study 24841352 — intervention group
Group type: COMPARATOR
Intervention: Internal jugular vein access
Number of subjects: 403
Study 24841352 — intervention group
Group type: COMPARATOR
Intervention: Cephalic vein access
Number of subjects: 403
Study 24841352 — intervention group
Group type: COMPARATOR
Intervention: Subclavian vein access
Number of subjects: 403
Study 24841352 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost analysis
Number of subjects: 403
Study 22980373 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril 10mg
Number of subjects: 24
Study 19578247 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily LPV/r 460/115 mg/m(2) plus two NRTIs
Number of subjects: 7
Study 19578247 — intervention group
Group type: COMPARATOR
Intervention: Twice-daily LPV/r 230/57.5 mg/m(2) plus two NRTIs
Number of subjects: 7
Study 17478409 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet and mobile phone-based physical activity program (n = 47)
Number of subjects: 77
Study 17478409 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 30)
Number of subjects: 77
Study 15001452 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone 4 mg daily for the initial 8 weeks, then doubled for the remainder of the study
Number of subjects: 92
Study 15001452 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 15001452 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 92
Study 12566891 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol 0.1% gel
Number of subjects: 210
Study 12566891 — intervention group
Group type: COMPARATOR
Intervention: Timolol 0.5% solution
Number of subjects: 210
Study 12566891 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of both interventions
Number of subjects: 210
Study 11738915 — intervention group
Group type: EXPERIMENTAL
Intervention: Curettage of the entire anterior capsule (Group A)
Number of subjects: 40
Study 11738915 — intervention group
Group type: COMPARATOR
Intervention: Curettage of the nasal half of the anterior capsule (Group B)
Number of subjects: 40
Study 9039173 — intervention group
Group type: EXPERIMENTAL
Intervention: Tretinoin cream 0.025%
Number of subjects: 32
Study 9039173 — intervention group
Group type: COMPARATOR
Intervention: Vehicle treatment
Number of subjects: 32
Study 8519047 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine 30 mg TID orally for 3 months
Number of subjects: 755
Study 8519047 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine 30 mg TID orally for 6 months
Number of subjects: 755
Study 3459860 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% chlorhexidine gel used twice a day
Number of subjects: 20
Study 3459860 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 20
Study 3459860 — intervention group
Group type: EXPERIMENTAL
Intervention: Ordinary toothpaste
Number of subjects: 20
Study 3459860 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% chlorhexidine gel
Number of subjects: 20
Study 29273232 — intervention group
Group type: EXPERIMENTAL
Intervention: Water resistance therapy
Number of subjects: 84
Study 29273232 — intervention group
Group type: EXPERIMENTAL
Intervention: Raspberry (tongue and lip trills)
Number of subjects: 84
Study 29273232 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongue trills
Number of subjects: 84
Study 29273232 — intervention group
Group type: EXPERIMENTAL
Intervention: Lip trills
Number of subjects: 84
Study 29273232 — intervention group
Group type: EXPERIMENTAL
Intervention: All exercises
Number of subjects: 84
Study 29273232 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective variables
Number of subjects: 84
Study 27395349 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/Valsartan
Number of subjects: 8381
Study 27395349 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 8381
Study 25268800 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-aortic balloon counterpulsation pump (IABP)
Number of subjects: 973
Study 25268800 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 973
Study 22813225 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium fluoride (NaF) varnish or solution (Treatment A)
Number of subjects: 13
Study 22813225 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium tetrafluoride (TiF(4)) varnish or solution (Treatment B)
Number of subjects: 13
Study 22813225 — intervention group
Group type: COMPARATOR
Intervention: Placebo varnish or no treatment (Treatment C)
Number of subjects: 13
Study 22813225 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium tetrafluoride (TiF(4)) formulations
Number of subjects: 13
Study 20383773 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-Intermittent (SI) protocol: 30 s at 110% of maximal aerobic velocity (MAV) with 30 s recovery at 50%
Number of subjects: 9
Study 20383773 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-Intermittent (LI) protocol: 3 min at 95% of MAV with 3 min recovery at 35%
Number of subjects: 9
Study 20383773 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy Continuous (HC) protocol: at 83% of MAV
Number of subjects: 9
Study 19208963 — intervention group
Group type: COMPARATOR
Intervention: Cognitive tasks (auditory frequency and lateralization disjunctive reaction time tasks, silent and audible backward counting, question-response clinical standard task) during sinusoidal earth-vertical axis rotation (EVAR) at 0.02 Hz, 0.05 Hz, and 0.1 Hz
Number of subjects: 29
Study 19208963 — intervention group
Group type: COMPARATOR
Intervention: Auditory DRT tasks during EVAR at 0.02 Hz, 0.05 Hz, and 0.1 Hz
Number of subjects: 29
Study 15693825 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C gum (60 mg, Series I)
Number of subjects: 30
Study 15693825 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C + carbamide gum (30 mg + 30 mg, Series II)
Number of subjects: 30
Study 15693825 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-vitamin C gum (Series I)
Number of subjects: 30
Study 15693825 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C + carbamide gum (30 mg + 30 mg)
Number of subjects: 30
Study 15693825 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C gum (30 mg)
Number of subjects: 30
Study 15693825 — intervention group
Group type: COMPARATOR
Intervention: No gum (negative control)
Number of subjects: 30
Study 12622502 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide in oxygen
Number of subjects: 135
Study 12622502 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (20 mg)‐propofol mixture
Number of subjects: 135
Study 12622502 — intervention group
Group type: COMPARATOR
Intervention: Propofol alone (control)
Number of subjects: 135
Study 10333897 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-glycemic index diet
Number of subjects: 20
Study 10333897 — intervention group
Group type: COMPARATOR
Intervention: High-glycemic index diet
Number of subjects: 20
Study 8624083 — intervention group
Group type: COMPARATOR
Intervention: AF102B (40 mg, tid, po)
Number of subjects: 0
Study 8624083 — intervention group
Group type: COMPARATOR
Intervention: AF102B (60 mg, tid, po)
Number of subjects: 0
Study 8624083 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1760811 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 x 10(6) IU or 12 x 10(6) IU Cetus IL-2/m2 by i.v. bolus daily for 5 consecutive days on weeks 1, 3 and 5
Number of subjects: 23
Study 31362993 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 mg once daily
Number of subjects: 0
Study 31362993 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab+MTX
Number of subjects: 0
Study 31362993 — intervention group
Group type: COMPARATOR
Intervention: Placebo+MTX
Number of subjects: 0
Study 28187726 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers In Motion (MIM) intervention
Number of subjects: 612
Study 28187726 — intervention group
Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 612
Study 26105109 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA
Number of subjects: 23
Study 26105109 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 24820046 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 cobalt gray equivalents (CGE) of PBI
Number of subjects: 46
Study 24820046 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 cobalt gray equivalents (CGE) of PBI
Number of subjects: 46
Study 24820046 — intervention group
Group type: COMPARATOR
Intervention: Mild radiation complications
Number of subjects: 46
Study 21394458 — intervention group
Group type: EXPERIMENTAL
Intervention: MC5-A Calmare© device
Number of subjects: 73
Study 18977274 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory P300 event‐related potential (ERP) in euthymic bipolar patients
Number of subjects: 62
Study 18977274 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance on Sustained Attention in euthymic bipolar patients
Number of subjects: 62
Study 18977274 — intervention group
Group type: COMPARATOR
Intervention: Auditory P300 event‐related potential (ERP) in healthy volunteers
Number of subjects: 62
Study 17200869 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffusion tensor imaging (DTI) and tractography (DTT)
Number of subjects: 0
Study 15195895 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) 750 mg daily
Number of subjects: 25
Study 15195895 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 11148740 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive transurethral microwave thermotherapy
Number of subjects: 0
Study 11148740 — intervention group
Group type: COMPARATOR
Intervention: Medical management (alpha-blockade)
Number of subjects: 0
Study 11148740 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant and adjuvant alpha-blocker therapy
Number of subjects: 0
Study 9537785 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen challenge in allergic patients
Number of subjects: 2
Study 9537785 — intervention group
Group type: EXPERIMENTAL
Intervention: Methacholine challenge in allergic and non-allergic subjects
Number of subjects: 2
Study 9537785 — intervention group
Group type: EXPERIMENTAL
Intervention: Methacholine stimulation of basophils in vitro
Number of subjects: 2
Study 9537785 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal lavage fluid analysis
Number of subjects: 2
Study 8018020 — intervention group
Group type: EXPERIMENTAL
Intervention: methyldopa
Number of subjects: 21
Study 8018020 — intervention group
Group type: EXPERIMENTAL
Intervention: propranolol
Number of subjects: 21
Study 8018020 — intervention group
Group type: EXPERIMENTAL
Intervention: atenolol
Number of subjects: 21
Study 8018020 — intervention group
Group type: EXPERIMENTAL
Intervention: hydrochlorothiazide‐triamterene
Number of subjects: 21
Study 8018020 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 21
Study 2562825 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol 400 mg
Number of subjects: 10
Study 2562825 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg
Number of subjects: 10
Study 2562825 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 590600 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinidazole (2 g single dose for 3 days)
Number of subjects: 60
Study 590600 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole (2 g single dose for 3 days)
Number of subjects: 60
Study 590600 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinidazole
Number of subjects: 60
Study 590600 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole
Number of subjects: 60
Study 31837317 — intervention group
Group type: EXPERIMENTAL
Intervention: Defocus Incorporated Multiple Segments (DIMS) lens
Number of subjects: 20
Study 31837317 — intervention group
Group type: COMPARATOR
Intervention: Single vision (SV) lens
Number of subjects: 20
Study 31203982 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (EX) - exercised to expend approximately 15% of digestible energy requirements for 4 weeks
Number of subjects: 10
Study 31203982 — intervention group
Group type: COMPARATOR
Intervention: Diet (DIET) - intake restricted to approximately 85% of digestible energy requirements for 4 weeks
Number of subjects: 10
Study 31203982 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (DIET and EX)
Number of subjects: 10
Study 27287069 — intervention group
Group type: EXPERIMENTAL
Intervention: LM50
Number of subjects: 328
Study 27287069 — intervention group
Group type: COMPARATOR
Intervention: LM25
Number of subjects: 328
Study 26501007 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (500mg orally one hour prior to extraction and 160mg gel foam soaked in tranexamic acid placed into the extraction socket postoperatively)
Number of subjects: 60
Study 26501007 — intervention group
Group type: COMPARATOR
Intervention: Placebo (crocin orally one hour prior to extraction and gel foam soaked in saline placed into the extraction socket postoperatively)
Number of subjects: 60
Study 23872699 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-week, self-guided, online, mindfulness-based intervention
Number of subjects: 104
Study 23872699 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 104
Study 21866716 — intervention group
Group type: EXPERIMENTAL
Intervention: Group psychoeducational music therapy songwriting session concerning coping skills
Number of subjects: 89
Study 21866716 — intervention group
Group type: COMPARATOR
Intervention: Group psychoeducational session concerning coping skills (Control)
Number of subjects: 89
Study 19515178 — intervention group
Group type: EXPERIMENTAL
Intervention: Bladder neck obstruction (42 men)
Number of subjects: 71
Study 19515178 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostatic obstruction (29 men)
Number of subjects: 71
Study 19515178 — intervention group
Group type: COMPARATOR
Intervention: Overall assessment
Number of subjects: 71
Study 16401736 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine 20 mg daily
Number of subjects: 175
Study 15529902 — intervention group
Group type: EXPERIMENTAL
Intervention: Two newsletters per week for 6 weeks
Number of subjects: 0
Study 15529902 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 0
Study 11122287 — intervention group
Group type: EXPERIMENTAL
Intervention: Contralateral turbinectomy
Number of subjects: 26
Study 11122287 — intervention group
Group type: COMPARATOR
Intervention: No turbinate surgery
Number of subjects: 26
Study 9295241 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.03% tacrolimus ointment
Number of subjects: 213
Study 9295241 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% tacrolimus ointment
Number of subjects: 213
Study 9295241 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% tacrolimus ointment
Number of subjects: 213
Study 9295241 — intervention group
Group type: COMPARATOR
Intervention: Vehicle alone
Number of subjects: 213
Study 9295241 — intervention group
Group type: EXPERIMENTAL
Intervention: All tacrolimus groups
Number of subjects: 213
Study 8313931 — intervention group
Group type: EXPERIMENTAL
Intervention: Deflazacort (DFZ)
Number of subjects: 30
Study 8313931 — intervention group
Group type: COMPARATOR
Intervention: Prednisone (PDN)
Number of subjects: 30
Study 3524226 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted insulin dosage decision-making (n = 7)
Number of subjects: 16
Study 3524226 — intervention group
Group type: COMPARATOR
Intervention: Standard algorithms for insulin adjustment (n = 9)
Number of subjects: 16
Study 3524226 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 16
Study 30975178 — intervention group
Group type: EXPERIMENTAL
Intervention: suPAR measurement
Number of subjects: 4420
Study 30975178 — intervention group
Group type: COMPARATOR
Intervention: Triage alone
Number of subjects: 4420
Study 28524639 — intervention group
Group type: EXPERIMENTAL
Intervention: IVPM (1000 mg methylprednisolone)
Number of subjects: 34
Study 28524639 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 25439614 — intervention group
Group type: EXPERIMENTAL
Intervention: Prompt laser treatment
Number of subjects: 235
Study 25439614 — intervention group
Group type: COMPARATOR
Intervention: Deferred laser treatment
Number of subjects: 235
Study 23819587 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Health Agents (CHA) introduced as part of health systems strengthening and referral improvement.
Number of subjects: 3300
Study 23819587 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Health Agents (CHA) with supervisory systems, information and monitoring operations, and logistics support.
Number of subjects: 3300
Study 21104229 — intervention group
Group type: EXPERIMENTAL
Intervention: Sagopilone
Number of subjects: 0
Study 21104229 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel
Number of subjects: 0
Study 19309251 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone plus metformin (15 mg/day for 12 weeks, then increased to 30 mg/day for 16 weeks)
Number of subjects: 236
Study 19309251 — intervention group
Group type: COMPARATOR
Intervention: Metformin monotherapy (500 or 750 mg/day)
Number of subjects: 236
Study 18690935 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenovirus
Number of subjects: 146
Study 18690935 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmid/liposomes
Number of subjects: 146
Study 18690935 — intervention group
Group type: EXPERIMENTAL
Intervention: Virus vectors
Number of subjects: 146
Study 18690935 — intervention group
Group type: COMPARATOR
Intervention: Randomized control patients
Number of subjects: 146
Study 15041104 — intervention group
Group type: EXPERIMENTAL
Intervention: Darifenacin 7.5 mg
Number of subjects: 561
Study 15041104 — intervention group
Group type: EXPERIMENTAL
Intervention: Darifenacin 15 mg
Number of subjects: 561
Study 15041104 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 561
Study 11775087 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy (antidepressants)
Number of subjects: 0
Study 11775087 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapies (pharmacotherapy with psychotherapy or electroconvulsive therapy)
Number of subjects: 0
Study 9041902 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-based pillow
Number of subjects: 41
Study 9041902 — intervention group
Group type: COMPARATOR
Intervention: Roll pillow
Number of subjects: 41
Study 9041902 — intervention group
Group type: COMPARATOR
Intervention: Standard pillow (usual pillow)
Number of subjects: 41
Study 7949101 — intervention group
Group type: EXPERIMENTAL
Intervention: FISH analysis for 12p13 translocations
Number of subjects: 20
Study 7949101 — intervention group
Group type: EXPERIMENTAL
Intervention: FISH analysis for 12p deletions
Number of subjects: 20
Study 7949101 — intervention group
Group type: EXPERIMENTAL
Intervention: FISH analysis for both del(12p) and 12p13 translocation
Number of subjects: 20
Study 7949101 — intervention group
Group type: EXPERIMENTAL
Intervention: Study of YAC clones spanning 12p13 translocation breakpoints
Number of subjects: 20
Study 7949101 — intervention group
Group type: EXPERIMENTAL
Intervention: FISH analysis using YACs for del(12p)
Number of subjects: 20